Tranexamic acid (TXA), an inhibitor of fibrinolysis blocking the lysine-binding site of plasminogen to fibrin, has been reported to reduce intraoperative and postoperative blood loss in patients undergoing primary total hip arthroplasty (PTHA) both with and without cement. Both intravenous (IV) and topical (TOP) administration of TXA can effectively reduce blood loss in THA without increasing risk of deep venous thrombosis (DVT). However, there have been few reports investigating the combination of intravenous and topical administration of TXA in bilateral cementless PTHA. We investigated the effects of combined intravenous and topical administration of TXA on postoperative blood loss, drainage volume, and perioperative complications in patients with bilateral simultaneous cementless PTHA for hip osteoarthritis. We retrospectively reviewed the demographic and clinical data of 41 patients who underwent bilateral simultaneous cementless PTHA for hip osteoarthritis from May 2015 to January 2017, of which there were 29 male (70.7%) and 12 female (29.3%) patients. Patients in IV group (n= 11) received only TXA (15 mg/kg) 10 min prior to the incision of each side; and patients in IV + TOP group (n=13) received i.v. TXA (15 mg/kg) combined with topical adiministration (1.0 g) of TXA during the each THA procedure; patients in control group (n=17) received the same dosage of normal saline both i.v. and topically. Outcome measures were total blood loss, hemoglobin, hematocrit value (HCT) changes preoperatively, and on the 1st, 3rd postoperative day, the amount of drainage, and perioperative complications.Objectives
Patients and methods
Although most joint surgeons have reached a consensus that preoperative risk assessment and appropriate medical intervention for elderly patients of primary total hip arthrplasty (PTHA) could significantly reduce postoperative complications and mortality, there is still lack of a detailed and comprehensive approach for risk stratifying and a systematic method for risk allaying. We aimed to explore the risk factors related to the aggravation of preoperative complications and the appearance of complications post-operation of primary total hip arthrplasty (PTHA) in elderly patients for hip fracture. We retrospectively reviewed the demographic and clinical data of 156 patients who underwent PTHA for hip fracture from January 2014 to December 2016, of which there were 61 male (39.1%) and 95 female (60.9%) patients; 111 patients aged 60–79 years (71.2%) and 45 patients ≥ 80 years old (28.8%); 125 patients of femoral neck fracture (80.1%) and 31 patients of inter-trochanteric fracture (19.9%); 109 patients of spinal anesthesia (69.9%) and 48 patients of general anesthesia (30.1%); 85 patients undergoing surgery within 3 days (54.5%) and 71 patients operated ≥ 4 days (45.5%) since admission. We evaluated the correlations among gender, age, type of fracture, methods of anesthesia, time of operation since admission, the aggravation of preoperative complications and the appearance of postoperative complications post PTHA using the IBM SPSS Statistics (version 21) and the Exce1 2016.Objectives
Patients and methods
Zirconia ceramic femoral head has better mechanical properties than those alumina head has. However, it is concerning whether the wear of UHMWPE against zirconia head is as low as that of alumina head. We compared polyethylene wears against 22.225mm alumina and zirconia heads in total hip arthroplasties (THA) occupied in our hospital. Kobelco hip prostheses (Kobelco, Kobe, Japan) were used. Titanium alloy stem was cement-fixed and all-polyethylene acetabular components were articulated with alumina or zirconia femoral heads. In the cases from February 1996 to December 1998, 96 primary cemented total hip arthroplasties (THA) in 87 patients of osteoarthritis were observed with a minimum follow-up of five years. The clinical results were evaluated using JOA hip score (100 in normal hip). There were 46 hips with alumina heads and mean follow-up of 6.2 years, and 51 hips with zirconiaheads and mean follow-up of 5.2 years. Mean ages at operation were 58 years. For each patient, the initial postoperative and the latest anterior-posterior radiographs of the pelvis were selected. With the custom software Image-Pro Plus version 4.0, linear wear and volumetric wear were measured. Clinical results of both heads showed no difference. Linear wear rate of alumina is 0.080±0.047mm/year, while it is 0.147±0.069mm/year for zirconia, significantly higher than alumina (p?0.0001). Volumetric wear rate of zirconia (42.499±20.233mm3/year) is also significantly higher than alumina (27.049±17.216mm3/year) (p?0.0001). The low thermal conductivity of zirconia is thought to cause local high temperature, leading to the phase transformation and lower-temperature aging degeneration (LTAD) of zirconia head surface. In order to solve this problem, alumina-adding zirconia compound ceramics with lower phase transformation were developed. Hip simulator test revealed much lower wear rate of improved zirconia. This will be discussed.
